Oral Muvalaplin for Lowering of Lipoprotein(a) This randomized clinical trial assesses the effect of muvalaplin on lipoprotein(a) concentrations in patients with high baseline lipoprotein(a) levels and cardiovascular risk factors.

Muvalaplin reduce la lipoproteína(a) usando pruebas de lipoproteína(a) intacta y apolipoproteína(a), siendo bien tolerada #muvalaplin #lipoprotein jamanetwork.com/journals/jam...

#CardioSky #Muvalaplin

My comments on the KRAKEN trial of #muvalaplin to Medscape. #lipids #LPa #CardioSky #AHA24

First investigational oral therapy lowers Lp(a) in phase 2 study CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data ...

#Muvalaplin #Lpa lowering. #KRAKEN trial at #AHA24. #CardioSky
www.healio.com/news/cardiol...

#AHA24 Please stay around to this afternoon's late breaking clinical trial session on #lipids! Phase 2 data for 2 new #LPa therapeutics ( #zerlasiran & #muvalaplin)
and phase 3 data of #obicetrapib for LDL-C lowering in HeFH. #CardioSky @ahascience.bsky.social